Phase II Evaluation of Safety, Tolerability, and Efficacy of BI 730357 in Patients With Moderate-to-severe Plaque Psoriasis
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Nov 2019
Price : $35 *
At a glance
- Drugs BI 730357 (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 13 Aug 2019 Planned End Date changed from 10 Jan 2020 to 7 Feb 2020.
- 13 Aug 2019 Planned primary completion date changed from 20 Sep 2019 to 18 Oct 2019.
- 13 Aug 2019 Status changed from recruiting to active, no longer recruiting.